Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.

Urol Oncol. 2013 Jul;31(5):566-71. doi: 10.1016/j.urolonc.2011.04.001. Epub 2011 May 19.

2.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

3.

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.

4.

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.

PMID:
22821767
5.

Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.

Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, Klapsas V, Synesiou M, Apostolaki A, Trangas T, Pandis N.

Anticancer Res. 2013 Jan;33(1):191-7.

PMID:
23267145
6.

Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Feng Z, Smith SS.

Clin Chem. 2008 Dec;54(12):2007-17. doi: 10.1373/clinchem.2008.108845. Epub 2008 Oct 23.

7.

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.

Clin Cancer Res. 2007 Sep 1;13(17):5103-8.

8.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
9.

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.

Anticancer Res. 2016 Sep;36(9):4787-93.

PMID:
27630329
10.

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A; Triptocare Study Group.

BJU Int. 2014 Oct;114(4):608-16. doi: 10.1111/bju.12542. Epub 2014 Apr 4.

11.

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

Salagierski M, Schalken JA.

J Urol. 2012 Mar;187(3):795-801. doi: 10.1016/j.juro.2011.10.133. Epub 2012 Jan 15. Review.

PMID:
22245323
12.

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators.

Clin Cancer Res. 2013 May 1;19(9):2442-50. doi: 10.1158/1078-0432.CCR-12-3283. Epub 2013 Mar 20.

13.

Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.

Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17.

14.

Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.

Sanguedolce F, Cormio A, Brunelli M, D'Amuri A, Carrieri G, Bufo P, Cormio L.

Clin Genitourin Cancer. 2016 Apr;14(2):117-21. doi: 10.1016/j.clgc.2015.12.001. Epub 2015 Dec 17. Review.

PMID:
26774207
15.

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.

Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T.

BJU Int. 2013 May;111(6):928-33. doi: 10.1111/j.1464-410X.2012.11683.x. Epub 2013 Jan 18.

16.

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.

Cancer Res. 2008 Feb 1;68(3):645-9. doi: 10.1158/0008-5472.CAN-07-3224.

17.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

18.

Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.

Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):100-5. doi: 10.1038/pcan.2011.52. Epub 2011 Nov 1.

19.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

20.

A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.

Donovan MJ, Noerholm M, Bentink S, Belzer S, Skog J, O'Neill V, Cochran JS, Brown GA.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):370-5. doi: 10.1038/pcan.2015.40. Epub 2015 Sep 8.

PMID:
26345389

Supplemental Content

Support Center